We treated nine patients who had carcinoid tumors of the small intestine, six of whom had the carcinoid syndrome, with daily intramuscular doses of leukocyte interferon--3 X 10(6) U per day for one month and 6 X 10(6) U per day for another two months. Seven patients had previously been treated with streptozocin and fluorouracil, without benefit. Treatment with interferon ameliorated the manifestations of the carcinoid syndrome and led to prompt and continuing decreases in urinary levels of 5-hydroxyindoleacetic acid and serum levels of human chorionic gonadotropin subunits and pancreatic polypeptide in all six patients with liver metastases, but it had no clear effect in two of three patients with only lymph-node involvement. After the treatment period, five of the six responders had relapses in clinical manifestations and increases in hormone levels. We conclude that interferon is of benefit in treating metastatic small intestinal carcinoid tumors in patients with the carcinoid syndrome.
This article has been cited by other articles:
Dahan, L., Bonnetain, F., Rougier, P., Raoul, J.-L., Gamelin, E., Etienne, P.-L., Cadiot, G., Mitry, E., Smith, D., Cvitkovic, F., Coudert, B., Ricard, F., Bedenne, L., Seitz, J.-F., for the Federation Francophone de Cancerologie Dig,
(2009). Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon {alpha} for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer
16: 1351-1361
[Abstract][Full Text]
Kvols, L. K.
(2008). Revisiting C.G. Moertel's Land of Small Tumors. JCO
26: 5005-5007
[Full Text]
Kulke, M. H
(2007). Gastrointestinal neuroendocrine tumors: a role for targeted therapies?. Endocr Relat Cancer
14: 207-219
[Abstract][Full Text]
Ramage, J K, Davies, A H G, Ardill, J, Bax, N, Caplin, M, Grossman, A, Hawkins, R, McNicol, A M, Reed, N, Sutton, R, Thakker, R, Aylwin, S, Breen, D, Britton, K, Buchanan, K, Corrie, P, Gillams, A, Lewington, V, McCance, D, Meeran, K, Watkinson, A, on behalf of UKNETwork for neuroendocrine tumours,
(2005). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut
54: iv1-iv16
[Full Text]
Filosso, P. L., Ruffini, E., Oliaro, A., Rena, O., Casadio, C., Mancuso, M., Turello, D., Cristofori, R. C., Maggi, G.
(2005). Large-cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J. Thorac. Cardiovasc. Surg.
129: 819-824
[Abstract][Full Text]
Faiss, S., Pape, U.-F., Bohmig, M., Dorffel, Y., Mansmann, U., Golder, W., Riecken, E. O., Wiedenmann, B.
(2003). Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors--The International Lanreotide and Interferon Alfa Study Group. JCO
21: 2689-2696
[Abstract][Full Text]
Wymenga, A.N.M., Eriksson, B., Salmela, P.I., Jacobsen, M.B., Van Cutsem, E.J.D.G., Fiasse, R.H., Valimaki, M.J., Renstrup, J., de Vries, E.G.E., Oberg, K.E.
(1999). Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms. JCO
17: 1111-1111
[Abstract][Full Text]
Kulke, M. H., Mayer, R. J.
(1999). Carcinoid Tumors. NEJM
340: 858-868
[Full Text]
Öberg, K.
(1998). Carcinoid Tumors: Current Concepts in Diagnosis and Treatment. The Oncologist
3: 339-345
[Abstract][Full Text]
Ronnblom, L. E., Alm, G. V., Oberg, K. E.
(1991). Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors. ANN INTERN MED
115: 178-183
[Abstract]
Strayer, D. R., Carter, W. A., Brodsky, I., Curley, R. M., Gain, T.
(1984). Carcinoid Tumor Response to Fibroblast Interferon. JAMA
251: 1682-1683
[Abstract]
